Bristol Myers to pay $11.1B to develop BioNTech cancer drug

Bristol Myers Squibb agreed to license a next-generation cancer drug from BioNTech SE for up to $11.1 billion.

Why it matters: The deal could help Bristol Myers fill a potential $9.3 billion hole when the patent for one of its bestsellers expires in 2028.